Navigation Links
PETA files complaint with European ombudsman over animal testing for REACH
Date:7/27/2012

London The People for the Ethical Treatment of Animals (PETA) Foundation UK has submitted a complaint to the European ombudsman today alleging that the European Chemicals Agency (ECHA) is failing to fulfil its mandated responsibilities by not properly investigating cases in which animal testing could be avoided under the rules of REACH. The European ombudsman investigates complaints about maladministration in EU institutions and agencies, and PETA maintains that evidence derived from public documents and correspondence with the agency demonstrates that ECHA is not taking the necessary steps to ensure that REACH's legal requirement that animal testing be conducted only as a "last resort" are fulfilled.

The REACH Regulation (1907/2006/EU) makes clear in recitals, articles and annexes that animal tests must be avoided wherever possible, but in 2011 the agency's report "The Use of Alternatives to Testing on Animals for the REACH Regulation" showed that tens of thousands of animals were used in tests that could have been avoided under REACH's own rules. These tests included 135 skin-irritation studies conducted after a non-animal replacement had been validated and approved for use under REACH and 107 studies conducted without prior submission and approval of a testing proposal.

In response to the report, PETA UK contacted ECHA and the European Commission to seek assurances that all such possible violations of the requirements were being investigated by the agency and/or notified to relevant national authorities. These enquiries have revealed the following:

  1. ECHA is not taking action to investigate all the 107 tests conducted without test proposals and will not routinely investigate similar cases in the future.
  2. ECHA does not directly inform member state authorities of all possible violations of last-resort requirements identified by its own internal processes.
  3. During compliance checks, ECHA evaluates only whether or not adaptations to animal test requirements comply with the REACH Regulation, not whether animal tests themselves could have been avoided.

PETA UK has therefore submitted a complaint to the ombudsman, which notes that in failing to take appropriate action to evaluate compliance of animal tests with REACH's requirements, the agency is guilty of maladministration.

"REACH has multiple mechanisms to mitigate its massive impact on animals, but the European institution responsible for ensuring REACH compliance is simply not ensuring that all of those mechanisms are being implemented," says PETA UK policy adviser Alistair Currie. "We have pursued this issue with ECHA itself and with the European Commission but without resolution. With millions of animals' lives at stake, we trust that the ombudsman will take our view that the agency is failing to fulfil its obligations."


'/>"/>

Contact: Jessica Sandler
JessicaS@PETA.org
757-622-7382 x8001
People for the Ethical Treatment of Animals
Source:Eurekalert

Related biology news :

1. Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
2. An invasive Asian fly is taking over European fruit
3. Building the European Unions Natura 2000 -- the largest ever network of protected areas
4. European grasslands challenge rainforests as the most species-rich spaces on Earth
5. European mountain plant population shows delayed response to climate change
6. European Society of Human Reproduction and Embryology 28th Annual Meeting -- Istanbul
7. Citizen science helps unlock European genetic heritage
8. Parkinsons disease stopped in animal model
9. Study suggests why some animals live longer
10. Are we really a nation of animal lovers?
11. NOAA discovers way to detect low-level exposure to seafood toxin in marine animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... replacement at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica ... technology and host a hands-on workshop for surgeons to experience the simplicity of ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... endeavors to bring to market a pioneering medical device for the treatment of ... an engagement contract with Emergo, a global regulatory consultancy that helps companies like ...
(Date:1/21/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, today presented data from two clinical ... 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers ... In a Phase Ib/II study of napabucasin ... cancer stemness pathways by targeting STAT3 – colorectal cancer ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
Breaking Biology Technology: